News Website

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.

Read Full Article

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology

Published: Nov. 12, 2025, 7:08 p.m.

Read Full Article

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma BioSpace

Published: Nov. 12, 2025, 4:01 a.m.

Read Full Article

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics - Frontiers

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics Frontiers

Published: Oct. 28, 2025, 4:44 p.m.

Read Full Article

Ovarian mesonephric-like adenocarcinoma mimicking serous carcinoma: A case report integrating cytologic, frozen, histological, immunohistochemistry, and molecular analyses.

Mesonephric-like adenocarcinoma (MLA) is a recently recognized, rare subtype of endometrial carcinoma that can also arise in the ovary. Ovarian MLA is uncommon and often misdiagnosed due to its varied …

Published: Oct. 25, 2025, midnight

Read Full Article

Case report Mesonephric-like adenocarcinoma Ovary Serous carcinoma

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas - Nature

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas Nature

Published: Oct. 20, 2025, 9:19 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.

Read Full Article

Can IVIM MRI be superior to ADC in predicting aggressive subtypes of endometrial carcinoma: new insights into FIGO 2023 classification - SpringerOpen

Can IVIM MRI be superior to ADC in predicting aggressive subtypes of endometrial carcinoma: new insights into FIGO 2023 classification SpringerOpen

Published: Oct. 10, 2025, 6:31 a.m.

Read Full Article

Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma - BMC Cancer

Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma BMC Cancer

Published: Oct. 9, 2025, 1:10 p.m.

Read Full Article

Latest Articles

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics - Frontiers

Ovarian mesonephric-like adenocarcinoma mimicking serous carcinoma: A case report integrating cytologic, frozen, histological, immunohistochemistry, and molecular analyses.

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas - Nature

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

Can IVIM MRI be superior to ADC in predicting aggressive subtypes of endometrial carcinoma: new insights into FIGO 2023 classification - SpringerOpen

Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma - BMC Cancer

Subscribe to Our Newsletter